Zymtronix
Zymtronix is a pre-commercial-stage biotechnology company that develops a patented cell-free enzyme biocatalysis platform originating from Cornell University, serving the agriculture (bioenhanced herbicides, biofungicides, sanitizers), nutrition (human milk oligosaccharides like DSLNT), and industrial biomanufacturing markets through direct sales and exclusive partnerships.
- Company typePrivate
- Founded2013
- HeadquartersIthaca, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Zymtronix does
Zymtronix is a pre-commercial-stage biotechnology company that develops a patented, cell-free enzyme biocatalysis platform originating from Cornell University research. The company eliminates the need for living cells, enabling production of complex molecules that cannot be made through traditional fermentation while improving production economics via a lower equipment footprint, reusable enzyme carriers, and simplified downstream processing. Its technology portfolio comprises three branded platforms: Crop-Core (agriculture), EX Enzyme Technology (herbicide enhancement), and Carbo Core (complex molecule production including human milk oligosaccharides).
The company commercializes across three product lines. In agriculture, it is developing BioEnhanced Herbicides (using EX Enzyme Technology to increase herbicide translocation and extend performance), Biofungicides (fast-acting antimicrobial compounds for targeted disease control), and Seed and Post-Harvest Sanitizers; commercialization of EX for vegetation management is planned for 2026-2027 under an exclusive partnership with The Orion Companies. In nutrition, Zymtronix commercially offers DSLNT (Disialyllacto-N-tetraose), a complex human milk oligosaccharide, to researchers and industrial partners. The company also operates an enzyme services platform for food, agriculture, cosmetics, and pharmaceutical ingredient production, in collaboration with Ginkgo Bioworks.
Zymtronix's business model combines pre-commercial product development with quote-based direct sales (DSLNT), exclusive channel partnerships (Orion for vegetation management), and a co-development relationship with Ginkgo Bioworks for upstream enzyme optimization. The company is venture-backed, has raised approximately $4.88M across six disclosed funding rounds through 2021 (with NSF as lead investor in early rounds), and is led by CEO Adam Monroe (former Novozymes President for North America) with founder Stéphane Corgié serving as Chief Innovation Officer. The company is headquartered in Durham, North Carolina, with research roots in Ithaca, New York.
Zymtronix firmographics
Firmographics- Name
- Zymtronix
- Legal name
- Zymtronix Catalytic Systems, Inc.
- Website
- https://zymtronix.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Zymtronix is a pre-commercial-stage biotechnology company that develops a patented cell-free enzyme biocatalysis platform originating from Cornell University, serving the agriculture (bioenhanced herbicides, biofungicides, sanitizers), nutrition (human milk oligosaccharides like DSLNT), and industrial biomanufacturing markets through direct sales and exclusive partnerships.
- Ownership category
- akta.pro rank
Zymtronix industry classification
Industry- Product category
- Industrial Biotechnology
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing (3253), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids) (EUAAAIAL)
- akta.pro secondary industries
- Biological Formulation, Fermentation & Scale-Up Manufacturing (AFABAEAM), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
Keywords
Where Zymtronix is headquartered
LocationHeadquarters
- HQ city
- Ithaca
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Zymtronix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Agricultural Products: Pre-commercial stage company developing and preparing to commercialize BioEnhanced Herbicides, BioFungicides, and Seed and Post-Harvest Sanitizers for the agriculture market. Revenue expected from product sales to farmers and agricultural companies.
- Human Milk Oligosaccharides: Commercial sales of DSLNT (Disialyllacto-N-tetraose) to researchers and industrial partners. Zymtronix now offers an economically viable and commercially available source of complex HMOs, selling directly to research institutions and companies.
- Technology Licensing: Exclusive partnership with The Orion Companies for development and commercialization of EX enzyme technology in vegetation management uses (industrial vegetation management, forestry, range & pasture). Expected commercialization in 2026-2027.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels4 records
Zymtronix product offering
Product offeringCore offering
Zymtronix develops and commercializes a proprietary cell-free, multi-enzyme biocatalysis platform that produces high-value industrial molecules without living cells, bypassing the limits of traditional fermentation. The platform underpins three product lines: BioEnhanced Herbicides and Biofungicides for agriculture, Seed and Post-Harvest Sanitizers, and complex Human Milk Oligosaccharides (notably DSLNT) for nutrition and microbiome research. The company also licenses its patented EX Enzyme Technology to commercial partners such as The Orion Companies for vegetation management.
Product overview
Zymtronix is a pre-commercial biotechnology company that offers a proprietary cell-free enzyme platform technology (Cell-Free Biocatalysis Platform) that overcomes traditional fermentation limitations. The platform is powered by the Crop-Core enzyme system and produces high-value industrial products across three main product lines: BioEnhanced Herbicides (using EX Enzyme Technology for enhanced weed control), Biofungicides (for targeted disease control), and Human Milk Oligosaccharides (HMOs including DSLNT) for nutrition applications. The company also offers Seed and Post-Harvest Sanitizers as part of its agricultural solutions portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- Crop-Core: The company's enzyme system that enables delivery of BioEnhanced Herbicides, BioFungicides, and Seed and Post-Harvest Sanitizers.
- Carbo Core
Products and services
- Cell-Free Biocatalysis Platform Proprietary cell-free enzyme platform that enables efficient production of high-value industrial molecules without living cells, overcoming the productivity, precision, and capital-cost limitations of traditional fermentation. Offered to industrial partners and researchers for co-development and licensing across food, agriculture, cosmetics, and pharmaceutical applications.
- BioEnhanced Herbicides Herbicide products that enhance traditional active ingredients with proprietary enzyme systems (Crop-Core / EX Enzyme Technology) to provide long-lasting, broad-spectrum weed control, increased herbicide translocation, extended performance, and improved consistency for conventional and organic growers.
- Biofungicides Enzyme-centered crop protection products that deliver fast-acting antimicrobial compounds to plant leaves for targeted, efficacious control of fungal and bacterial pathogens, addressing a critical shortage of effective treatments for organic and specialty crop growers.
- Seed and Post-Harvest Sanitizers Crop protection products enabled by the Crop-Core enzyme system that protect seeds and harvested crops from pathogens, intended to decrease financial risk and product variability for seed companies and post-harvest handlers.
- Human Milk Oligosaccharides (DSLNT) Complex human milk oligosaccharides (notably DSLNT / Disialyllacto-N-tetraose) produced via Zymtronix's cell-free biocatalysis platform, supplied to researchers and industrial partners in infant nutrition, microbiome science, and immunology to address a critical supply bottleneck for HMOs.
Quantifiable outcome
- Weeds cause over $55 billion in crop losses each year
- +3 more outcomes
Companies that use Zymtronix
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Zymtronix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Zymtronix partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- The Orion CompaniescoreExclusive agreement to develop and commercialize Zymtronix EX enzyme technology for herbicide application in vegetation management uses (industrial vegetation management, forestry, range & pasture). Companies began vegetation management field trials in 2024 and plan commercialization in 2026 and 2027 following promising results. The Orion Companies provides innovation to improve effectiveness and productivity of their applicator customers.
- Ginkgo BioworkscorePartnership to optimize enzymes used in Zymtronix's proprietary cell-free platform for production of ingredients in food, agriculture, cosmetics, and pharmaceuticals. Ginkgo leverages its enzyme services (discovery, optimization, production) including metagenomic enzyme discovery and improved enzyme expression and production host performance. This partnership accelerates commercialization of cell-free biomanufacturing and sustainable ingredients, starting with alternatives to animal sources.
Scale indicators5 records
Recent moves6 records
Zymtronix competitors and assessment
Company assessmentDirect peers
- Ginkgo Bioworks: Public synthetic biology platform company pursuing cell-free expression, enzyme engineering and biomanufacturing partnerships. Zymtronix's active partner (Feb 2023) and closest peer given overlapping cell-free/biocatalysis ambitions across pharma, food, and agriculture.
- Codexis: Public enzyme engineering company using directed evolution and biocatalysis platforms to produce pharmaceutical, food, and industrial ingredients. Closely comparable cell-free enzyme IP/development model to Zymtronix's core platform.
- AgBiome: Agriculture biologicals company developing microbial crop protection products, where board member John Rabby previously served as President and CEO. Closely comparable in the AgTech-biological product category Zymtronix is targeting with Crop-Core.
- Vestaron: Peptide-based bioinsecticide company for crop protection; CFO Jessica Vanhoy led its US$82M Series C. Closely comparable as a venture-backed ag-biological company commercializing novel modes of action in crop protection.
- Pivot Bio: Leading microbial nitrogen-fixation company for row crops; pursues commodity-scale agricultural biologicals with channel partnerships analogous to Zymtronix's Orion partnership for vegetation management.
Broad incumbents
- Novonesis (formerly Novozymes): Global leader in industrial enzymes and microbial bioproducts with deep crop protection and nutrition adjacencies. Zymtronix CEO Adam Monroe and board member Thomas Videbaek came from Novozymes, making it the most directly relevant incumbent benchmark.
- dsm-firmenich: Global nutrition/health ingredients major with HMO production (e.g., GlyCare) and industrial enzymes. Relevant comparison for both Zymtronix's DSLNT HMO business and its broader biomanufacturing ambitions.
- BASF Agricultural Solutions: Diversified crop protection and seed major where board member John Rabby previously served as Group VP North America. Relevant scale benchmark for traditional ag-chemical incumbents Zymtronix is differentiating against via enzyme-based biocontrol.
- Bayer Crop Science: Global crop protection and seed major with growing biologicals franchises. Relevant incumbent for the BioEnhanced Herbicides / Biofungicides competitive set and a credible future channel/licensing partner.
Emerging players
- Zymergen (now Ginkgo Bioworks): Synthetic biology company that has been folded into Ginkgo Bioworks; historically comparable as a platform player pursuing cell-free and engineered-organism routes to industrial bioproducts.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Zymtronix social profiles
Digital presenceZymtronix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Zymtronix leadership team
Management profileNumber of profiles
Profiles9 records
Zymtronix funding detail
Funding detailFunding overview
Funding rounds6 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Zymtronix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Zymtronix
What does Zymtronix do?
Zymtronix develops and commercializes a proprietary cell-free, multi-enzyme biocatalysis platform that produces high-value industrial molecules without living cells, bypassing the limits of traditional fermentation. The platform underpins three product lines: BioEnhanced Herbicides and Biofungicides for agriculture, Seed and Post-Harvest Sanitizers, and complex Human Milk Oligosaccharides (notably DSLNT) for nutrition and microbiome research. The company also licenses its patented EX Enzyme Technology to commercial partners such as The Orion Companies for vegetation management.
Is Zymtronix a public or private company?
Zymtronix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Zymtronix founded?
Zymtronix was founded in 2013. It employs 11 to 50 people.
Where is Zymtronix based?
Zymtronix is headquartered in Ithaca, United States, in the North America region.
How does Zymtronix make money?
Three revenue lines are on record. Agricultural Products are the primary driver. The others are human Milk Oligosaccharides and technology Licensing.
Who are Zymtronix's main competitors?
Direct peers on record are Ginkgo Bioworks, Codexis, AgBiome, Vestaron and Pivot Bio. Broad incumbents are Novonesis (formerly Novozymes), dsm-firmenich, BASF Agricultural Solutions and Bayer Crop Science. Zymergen (now Ginkgo Bioworks) is listed as an emerging player.
Does Zymtronix have an API?
No public API is recorded for Zymtronix.
What industry is Zymtronix in?
Zymtronix's product category is Industrial Biotechnology. Its primary akta.pro industry code is EUAAAIAL, Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids), with a secondary code of AFABAEAM, Biological Formulation, Fermentation & Scale-Up Manufacturing. Its NAICS code is 325411 and its SIC code is 2836.